日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans.

De Novo Germline L858R EGFR 变异与全身性黑棘皮病。

Jiang Xingyuan, Jeng Mark Y, Yang Zhou, Ugwu Nelson, Cheng Yuan, Echeandia-Francis Caroline, Mortlock Ryland D, Mani Mitra V, Rekhtman Natasha, Podolanczuk Anna J, Fiorino Elizabeth, Plodkowski Andrew, Lekwuttikarn Ramrada, Teng Joyce, Walsh Michael F, Yu Helena A, Lin Zhimiao, Choate Keith A

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Durvalumab联合化疗治疗一线奥希替尼治疗后疾病进展的EGFR突变晚期非小细胞肺癌患者:ORCHARD

Cho, Byoung Chul; Nishio, Makoto; Ahn, Myung-Ju; García-Campelo, Rosario; Ponce, Santiago; Baik, Christina; Salgia, Ravi; Kim, Sang-We; Lee, Jong Seok; Yoshida, Tatsuya; Yu, Helena A; Goldberg, Sarah B; Johannes de Langen, Adrianus; Le, Xiuning; Piotrowska, Zofia; Riess, Jonathan W; Tanaka, Kentaro; Ambrose, Helen; Cosaert, Jan; Fraenkel, Paula G; Tang, Kwan Ho; Lehman, Jonathan M; Smith, Paul; Goldman, Jonathan W

Evolution of oncogene amplification across 86,000 cancer cell genomes

86000个癌细胞基因组中癌基因扩增的演变

Lee, Jake June-Koo; Salehi, Sohrab; Myers, Matthew A; Williams, Marc J; Yao, Melissa A; Al-Rawi, Duaa H; Lee, Jin; Sun, Eric G; Thol, Kerstin; Choi, Seongmin; Havasov, Eliyahu; Steinberg, Asher Preska; Wu, Michelle; Rusk, Nicole; Timmons, Caitlin; Phua, Cheryl Zi Jin; Martis, Stephen; Mohibullah, Neeman; Manoj, Parvathy; Redin, Esther; Quintanal-Villalonga, Álvaro; Razavi, Pedram; Aparicio, Samuel; Rekhtman, Natasha; Tabar, Viviane; Awad, Mark M; Yu, Helena A; Yu, Kenny Kwok Hei; Ventura, Andrea; McPherson, Andrew; Rudin, Charles M; Shah, Sohrab P

Chromothripsis-Mediated Small Cell Lung Carcinoma

染色体碎裂介导的小细胞肺癌

Rekhtman, Natasha; Tischfield, Sam E; Febres-Aldana, Christopher A; Lee, Jake June-Koo; Chang, Jason C; Herzberg, Benjamin O; Selenica, Pier; Woo, Hyung Jun; Vanderbilt, Chad M; Yang, Soo-Ryum; Xu, Fei; Bowman, Anita S; da Silva, Edaise M; Noronha, Anne Marie; Mandelker, Diana L; Mehine, Miika; Mukherjee, Semanti; Blanco-Heredia, Juan; Orgera, John J; Nanjangud, Gouri J; Baine, Marina K; Aly, Rania G; Sauter, Jennifer L; Travis, William D; Savari, Omid; Moreira, Andre L; Falcon, Christina J; Bodd, Francis M; Wilson, Christina E; Sienty, Jacklynn V; Manoj, Parvathy; Sridhar, Harsha; Wang, Lu; Choudhury, Noura J; Offin, Michael; Yu, Helena A; Quintanal-Villalonga, Alvaro; Berger, Michael F; Ladanyi, Marc; Donoghue, Mark T A; Reis-Filho, Jorge S; Rudin, Charles M

Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity

肺癌与心血管疾病:共同的病理生理机制和治疗相关毒性

El-Rayes, Malak; Nardi Agmon, Inbar; Yu, Christopher; Osataphan, Nichanan; Yu, Helena A; Hope, Andrew; Sacher, Adrian; Yu, Anthony F; Abdel-Qadir, Husam; Thavendiranathan, Paaladinesh

Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

奥拉帕尼联合胸部放疗治疗广泛期小细胞肺癌的I期剂量递增试验

Rimner, Andreas; Lok, Benjamin H; Gelblum, Daphna Y; Kotecha, Rupesh R; Shin, Jacob Y; LaPlant, Quincey; Shepherd, Annemarie F; Shaverdian, Narek; Simone, Charles B; Ng, Vanessa J; Ionescu, Alexandru; Yu, Helena A; Daly, Robert; Offin, Michael D; Yorke, Ellen D; Ginsberg, Michelle S; Zhang, Zhigang; Wu, Abraham J; Rudin, Charles M

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.

不同MET肿瘤改变对I型和II型MET抑制剂的反应性

Murciano-Goroff Yonina R, Foglizzo Valentina, Chang Jason, Rekhtman Natasha, Sisk Ann Elizabeth, Gibson Jamie, Judka Lia, Clemens Kristen, Roa Paola, Ahmed Shaza Sayed, Bremer Nicole V, Binaco Courtney Lynn, Muzungu Sherifah Kemigisha, Rodriguez Estelamari, Merrill Madeline, Sgroe Erica, Repetto Matteo, Stadler Zsofia K, Berger Michael F, Yu Helena A, Toska Eneda, Kannan Srinivasaraghavan, Verma Chandra S, Drilon Alexander, Cocco Emiliano

Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib

接受奥希替尼治疗的 EGFR 突变型肺癌患者,其寡转移进展病灶接受放射治疗后的疗效

Chen, Monica F; Jeng, Mark Y; Ma, Jennifer; Agrawal, Prashasti; Dunne, Elizabeth; Boe, Lillian A; Kris, Mark G; Huang, James; Veeraraghavan, Harini; Gomez, Daniel; Yu, Helena A

Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers

EGFR突变型可切除非小细胞肺癌患者接受新辅助奥希替尼和/或化疗的疗效

Agrawal, Prashasti; Rotow, Julia; Rocco, Gaetano; Travis, William; Ortiz, Eduardo; Scalabrino, Rebecca; LoPiccolo, Jaclyn; Facchinetti, Francesco; Kris, Mark G; Yu, Helena A; Jones, David; Chaft, Jamie E

TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib

TROPION-Lung15:一项随机III期研究,比较奥希替尼联合达托泊单抗德鲁西替康(Dato-DXd)或单用Dato-DXd与铂类双药化疗在EGFR突变晚期非小细胞肺癌且既往接受奥希替尼治疗后病情进展的患者中的疗效。

Tan, Daniel Shao-Weng; Nadal, Ernest; Cheema, Parneet; Wu, Yi-Long; Ahn, Myung-Ju; Tanizaki, Junko; Grainger, Ellie; Nizialek, Emily; Forcina, Alessandra; van der Gronde, Toon; Yu, Helena A